bioAffinity Technologies/$BIAF
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About bioAffinity Technologies
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
- Ticker
- $BIAF
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 57
- Headquarters
- San Antonio, United States
- Website
- bioaffinitytech.com
BIAF Metrics
BasicAdvanced
$3.1M
-
-$33.31
-
-
Price and volume
Market cap
$3.1M
52-week high
$80.70
52-week low
$2.23
Average daily volume
1.3M
Financial strength
Current ratio
1.511
Quick ratio
1.3
Long term debt to equity
0.282
Total debt to equity
0.383
Interest coverage (TTM)
-270.95%
Profitability
EBITDA (TTM)
-13.233
Gross margin (TTM)
27.05%
Net profit margin (TTM)
-278.93%
Operating margin (TTM)
-246.14%
Effective tax rate (TTM)
-0.02%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-89.00%
Return on equity (TTM)
-240.48%
Valuation
Price to revenue (TTM)
0.203
Price to book
0.72
Price to tangible book (TTM)
1.54
Price to free cash flow (TTM)
-0.086
Free cash flow yield (TTM)
-1,161.85%
Free cash flow per share (TTM)
-28.173
Growth
Revenue change (TTM)
-18.47%
Earnings per share change (TTM)
-89.05%
3-year revenue growth (CAGR)
158.06%
3-year earnings per share growth (CAGR)
-55.67%
BIAF Financial Performance
Revenues and expenses
BIAF Earnings Performance
Company profitability
Upcoming events
No upcoming events
BIAF News
AllArticlesVideos
bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization
Business Wire6 days ago
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Business Wire1 month ago
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.